## Persistent LCMV Infection Is Controlled by Blockade of

Science 340, 207-211 DOI: 10.1126/science.1235214

Citation Report

#	Article	IF	CITATIONS
1	HIV-Associated Immune Activation: From Bench to Bedside. AIDS Research and Human Retroviruses, 2011, 27, 355-364.	1.1	105
2	Type I interferon regulation of natural killer cell function in primary and secondary infections. Expert Review of Vaccines, 2013, 12, 875-884.	4.4	22
3	An Interferon Paradox. Science, 2013, 340, 155-156.	12.6	55
4	Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology, 2013, 10, 146.	2.0	183
5	Confounding roles for type I interferons during bacterial and viral pathogenesis. International Immunology, 2013, 25, 663-669.	4.0	43
6	IRF3 helps control acute TMEV infection through IL-6 expression but contributes to acute hippocampus damage following TMEV infection. Virus Research, 2013, 178, 226-233.	2.2	20
7	Decoding the complexity of type I interferon to treat persistent viral infections. Trends in Microbiology, 2013, 21, 634-640.	7.7	23
8	Virus-associated activation of innate immunity induces rapid disruption of Peyer's patches in mice. Blood, 2013, 122, 2591-2599.	1.4	6
9	Networking at the Level of Host Immunity: Immune Cell Interactions during Persistent Viral Infections. Cell Host and Microbe, 2013, 13, 652-664.	11.0	79
10	The interferon paradox. Nature Reviews Immunology, 2013, 13, 392-393.	22.7	11
11	Dendritic cell dysregulation during <scp>HIV</scp> â€1 infection. Immunological Reviews, 2013, 254, 170-189.	6.0	95
12	A Bloody Mess: Dendritic Cells Use Hemophagocytosis to Regulate Viral Inflammation. Immunity, 2013, 39, 429-431.	14.3	1
13	Interfering with type I Interferon: A novel approach to purge persistent viral infection. Cell Cycle, 2013, 12, 2919-2920.	2.6	7
14	Absence of Siglec-H in MCMV Infection Elevates Interferon Alpha Production but Does Not Enhance Viral Clearance. PLoS Pathogens, 2013, 9, e1003648.	4.7	41
15	Type I Interferon Upregulates Bak and Contributes to T Cell Loss during Human Immunodeficiency Virus (HIV) Infection. PLoS Pathogens, 2013, 9, e1003658.	4.7	76
16	Transcriptional Analysis of Murine Macrophages Infected with Different Toxoplasma Strains Identifies Novel Regulation of Host Signaling Pathways. PLoS Pathogens, 2013, 9, e1003779.	4.7	111
17	Macrophage and T Cell Produced IL-10 Promotes Viral Chronicity. PLoS Pathogens, 2013, 9, e1003735.	4.7	55

#	Article	IF	CITATIONS
19	Induction of appropriate Th cell phenotypes: Cellular decision-making in heterogeneous environments. Parasite Immunology, 2013, 35, n/a-n/a.	1.5	7
20	Type I <scp>IFN</scp> Exhaustion is a Host Defence Protecting Against Secondary Bacterial Infections. Scandinavian Journal of Immunology, 2013, 78, 395-400.	2.7	8
21	Role of type I interferons in inflammasome activation, cell death, and disease during microbial infection. Frontiers in Cellular and Infection Microbiology, 2013, 3, 77.	3.9	84
23	NK Cells and Their Ability to Modulate T Cells during Virus Infections. Critical Reviews in Immunology, 2014, 34, 359-388.	0.5	85
24	Intact Dendritic Cell Pathogen-Recognition Receptor Functions Associate with Chronic Hepatitis C Treatment-Induced Viral Clearance. PLoS ONE, 2014, 9, e102605.	2.5	5
25	Increased Antigen Presentation but Impaired T Cells Priming after Upregulation of Interferon-Beta Induced by Lipopolysaccharides Is Mediated by Upregulation of B7H1 and GITRL. PLoS ONE, 2014, 9, e105636.	2.5	12
26	Role of MicroRNA Modulation in the Interferon-α/Ribavirin Suppression of HIV-1 In Vivo. PLoS ONE, 2014, 9, e109220.	2.5	7
27	IFN-Stimulated Gene LY6E in Monocytes Regulates the CD14/TLR4 Pathway but Inadequately Restrains the Hyperactivation of Monocytes during Chronic HIV-1 Infection. Journal of Immunology, 2014, 193, 4125-4136.	0.8	41
28	Strain-specific innate immune signaling pathways determine malaria parasitemia dynamics and host mortality. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E511-20.	7.1	74
29	Interferonâ€alpha, immune activation and immune dysfunction in treated HIV infection. Clinical and Translational Immunology, 2014, 3, e10.	3.8	59
30	Type I interferon is a therapeutic target for virus-induced lethal vascular damage. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8925-8930.	7.1	56
31	Dynamic Functional Modulation of CD4+ T Cell Recall Responses Is Dependent on the Inflammatory Environment of the Secondary Stimulus. PLoS Pathogens, 2014, 10, e1004137.	4.7	13
32	Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. Frontiers in Immunology, 2014, 5, 526.	4.8	54
33	Type I Interferons as Regulators of Human Antigen Presenting Cell Functions. Toxins, 2014, 6, 1696-1723.	3.4	83
34	Selection on a Variant Associated with Improved Viral Clearance Drives Local, Adaptive Pseudogenization of Interferon Lambda 4 (IFNL4). PLoS Genetics, 2014, 10, e1004681.	3.5	87
35	Reverse Translation in Tuberculosis: Neutrophils Provide Clues for Understanding Development of Active Disease. Frontiers in Immunology, 2014, 5, 36.	4.8	22
36	Plasmacytoid Dendritic Cells Suppress HIV-1 Replication but Contribute to HIV-1 Induced Immunopathogenesis in Humanized Mice. PLoS Pathogens, 2014, 10, e1004291.	4.7	100
37	STING-Dependent Type I IFN Production Inhibits Cell-Mediated Immunity to Listeria monocytogenes. PLoS Pathogens, 2014, 10, e1003861.	4.7	111

#	Article	IF	CITATIONS
38	Unraveling the Convoluted Biological Roles of Type I Interferons in Infection and Immunity: A Way Forward for Therapeutics and Vaccine Design. Frontiers in Immunology, 2014, 5, 412.	4.8	16
39	Multifaceted Activities of Type I Interferon Are Revealed by a Receptor Antagonist. Science Signaling, 2014, 7, ra50.	3.6	94
40	The Yin–Yang arms of vaccines: disease-fighting power versus tissue-destructive inflammation. Expert Review of Vaccines, 2014, 13, 417-427.	4.4	10
41	Therapeutic Activity of High-Dose Intratumoral IFN-Î <sup>2</sup> Requires Direct Effect on the Tumor Vasculature. Journal of Immunology, 2014, 193, 4254-4260.	0.8	79
42	Anti-GITR Agonist Therapy Intrinsically Enhances CD8 T Cell Responses to Chronic Lymphocytic Choriomeningitis Virus (LCMV), Thereby Circumventing LCMV-Induced Downregulation of Costimulatory GITR Ligand on APC. Journal of Immunology, 2014, 193, 5033-5043.	0.8	22
43	Systemic Factors Mediate Reversible Age-Associated Brain Dysfunction. Rejuvenation Research, 2014, 17, 525-528.	1.8	13
44	Monocyte Activation from Interferon- $\hat{l}_{\pm}$ in HIV Infection Increases Acetylated LDL Uptake and ROS Production. Journal of Interferon and Cytokine Research, 2014, 34, 822-828.	1.2	16
45	Resolution of acute inflammation bridges the gap between innate and adaptive immunity. Blood, 2014, 124, 1748-1764.	1.4	142
46	Hepatocyte growth factor in dampening liver immuneâ€mediated pathology in acute viral hepatitis without compromising antiviral activity. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 878-886.	2.8	7
47	Advances in understanding the role of type I interferons in systemic lupus erythematosus. Current Opinion in Rheumatology, 2014, 26, 467-474.	4.3	97
48	Therapeutic Depletion of Natural Killer Cells Controls Persistent Infection. Journal of Virology, 2014, 88, 1953-1960.	3.4	66
49	Type I Interferon Limits the Capacity of Bluetongue Virus To Infect Hematopoietic Precursors and Dendritic Cells <i>In Vitro</i> and <i>In Vivo</i> . Journal of Virology, 2014, 88, 859-867.	3.4	14
50	IL-10: Achieving Balance During Persistent Viral Infection. Current Topics in Microbiology and Immunology, 2014, 380, 129-144.	1.1	33
51	HCV-Induced Immune Responses Influence the Development of Operational Tolerance After Liver Transplantation in Humans. Science Translational Medicine, 2014, 6, 242ra81.	12.4	74
52	Type I Interferons in Bacterial Infections: Taming of Myeloid Cells and Possible Implications for Autoimmunity. Frontiers in Immunology, 2014, 5, 431.	4.8	43
53	Loss of the death receptor CD95 (Fas) expression by dendritic cells protects from a chronic viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8559-8564.	7.1	11
54	Dendritic cells in progression and pathology of HIV infection. Trends in Immunology, 2014, 35, 114-122.	6.8	78
55	The role of viral persistence in flavivirus biology. Pathogens and Disease, 2014, 71, 137-163.	2.0	44

#	Article	lF	Citations
56	Hantavirus GnT Elements Mediate TRAF3 Binding and Inhibit RIG-I/TBK1-Directed Beta Interferon Transcription by Blocking IRF3 Phosphorylation. Journal of Virology, 2014, 88, 2246-2259.	3.4	43
57	Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. Journal of Experimental Medicine, 2014, 211, 961-974.	8.5	150
58	Activation of endogenous type I IFN signaling contributes to persistent HCV infection. Reviews in Medical Virology, 2014, 24, 332-342.	8.3	19
59	Pharmacological Inhibition of Type I Interferon Signaling Protects Mice Against Lethal Sepsis. Journal of Infectious Diseases, 2014, 209, 960-970.	4.0	50
60	Regulation of type I interferon responses. Nature Reviews Immunology, 2014, 14, 36-49.	22.7	2,400
61	Immunopathogenesis of abdominal sepsis. Langenbeck's Archives of Surgery, 2014, 399, 1-9.	1.9	40
62	Type I IFN Induces Binding of STAT1 to Bcl6: Divergent Roles of STAT Family Transcription Factors in the T Follicular Helper Cell Genetic Program. Journal of Immunology, 2014, 192, 2156-2166.	0.8	95
63	Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends in Immunology, 2014, 35, 51-60.	6.8	513
64	Immune Responses to HCV and Other Hepatitis Viruses. Immunity, 2014, 40, 13-24.	14.3	236
65	Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity <i>In Vivo</i> . Journal of Virology, 2014, 88, 763-767.	3.4	29
66	Interleukin-10 in Health and Disease. Current Topics in Microbiology and Immunology, 2014, , .	1.1	13
67	Sendai Virus Pathogenesis in Mice Is Prevented by Ifit2 and Exacerbated by Interferon. Journal of Virology, 2014, 88, 13593-13601.	3.4	42
68	T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. Hepatology, 2014, 60, 1531-1540.	7.3	64
69	Protozoan parasites and type I interferons: a cold case reopened. Trends in Parasitology, 2014, 30, 491-498.	3.3	30
70	The Different Modes of Resistance to AIDS. , 2014, , 287-352.		1
71	Enhanced Innate Antiviral Gene Expression, IFN-α, and Cytolytic Responses Are Predictive of Mucosal Immune Recovery during Simian Immunodeficiency Virus Infection. Journal of Immunology, 2014, 192, 3308-3318.	0.8	9
72	Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA. European Journal of Immunology, 2014, 44, 2847-2853.	2.9	26
73	Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature, 2014, 511, 601-605.	27.8	422

#	Article	IF	CITATIONS
74	Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment. Nature Communications, 2014, 5, 3872.	12.8	37
75	IFNαR Signaling in Effector but Not Regulatory T Cells Is Required for Immune Dysregulation during Type I IFN–Dependent Inflammatory Disease. Journal of Immunology, 2014, 193, 2733-2742.	0.8	15
76	Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science, 2014, 346, 89-93.	12.6	463
77	A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells. Science, 2014, 346, 93-98.	12.6	353
78	Sex-Based Differences in HIV Type 1 Pathogenesis. Journal of Infectious Diseases, 2014, 209, S86-S92.	4.0	128
79	Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. Journal of Experimental Medicine, 2014, 211, 1905-1918.	8.5	182
80	Foxa3 Induces Goblet Cell Metaplasia and Inhibits Innate Antiviral Immunity. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 301-313.	5.6	122
81	Interferon regulatory factor 3 in adaptive immune responses. Cellular and Molecular Life Sciences, 2014, 71, 3873-3883.	5.4	45
82	Mucosal Polyinosinic-Polycytidylic Acid Improves Protection Elicited by Replicating Influenza Vaccines via Enhanced Dendritic Cell Function and T Cell Immunity. Journal of Immunology, 2014, 193, 1324-1332.	0.8	42
83	Pathogenic potential of interferon $\hat{I}\pm\hat{I}^2$ in acute influenza infection. Nature Communications, 2014, 5, 3864.	12.8	315
84	Reduction of HBV replication prolongs the early immunological response to IFNα therapy. Journal of Hepatology, 2014, 60, 54-61.	3.7	75
85	Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection. Immunity, 2014, 40, 289-302.	14.3	418
86	Targeting the Tumor Microenvironment with Interferon-Î <sup>2</sup> Bridges Innate and Adaptive Immune Responses. Cancer Cell, 2014, 25, 37-48.	16.8	236
87	Type I Interferon in the Pathogenesis of Lupus. Journal of Immunology, 2014, 192, 5459-5468.	0.8	439
88	Immunologic strategies for HIV-1 remission and eradication. Science, 2014, 345, 169-174.	12.6	193
89	Bystander Chronic Infection Negatively Impacts Development of CD8+ T Cell Memory. Immunity, 2014, 40, 801-813.	14.3	78
90	IFN-λ Exerts Opposing Effects on T Cell Responses Depending on the Chronicity of the Virus Infection. Journal of Immunology, 2014, 192, 3596-3606.	0.8	28
91	Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2014,	7.1	87

#	Article	IF	CITATIONS
92	The role of type I interferons in intestinal infection, homeostasis, and inflammation. Immunological Reviews, 2014, 260, 145-167.	6.0	60
93	Spatiotemporal requirements for IRF7 in mediating type I IFNâ€dependent susceptibility to bloodâ€stage <i>Plasmodium</i> infection. European Journal of Immunology, 2015, 45, 130-141.	2.9	21
94	Severity of DSS-induced colitis is reduced in Ido1-deficient mice with down-regulation of TLR-MyD88-NF-kB transcriptional networks. Scientific Reports, 2015, 5, 17305.	3.3	71
96	Sex Differences in Plasmacytoid Dendritic Cell Levels of IRF5 Drive Higher IFN-α Production in Women. Journal of Immunology, 2015, 195, 5327-5336.	0.8	186
97	Infectious Diseases in Transplantation—Report of the 20th Nantes Actualités Transplantation Meeting. Transplantation, 2015, 99, 2444-2447.	1.0	0
98	Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy. Oncolytic Virotherapy, 2015, 4, 183.	6.0	16
99	Macrophage Polarization in Virus-Host Interactions. Journal of Clinical & Cellular Immunology, 2015, 06, .	1.5	73
100	The Dual Role of Exosomes in Hepatitis A and C Virus Transmission and Viral Immune Activation. Viruses, 2015, 7, 6707-6715.	3.3	63
101	Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis. Journal of Immunology Research, 2015, 2015, 1-9.	2.2	21
102	IL-27 Suppresses Antimicrobial Activity in Human Leprosy. Journal of Investigative Dermatology, 2015, 135, 2410-2417.	0.7	25
103	<i>In Vitro</i> and <i>In Vivo</i> Characterizations of Pichinde Viral Nucleoprotein Exoribonuclease Functions. Journal of Virology, 2015, 89, 6595-6607.	3.4	42
104	New insights into the resolution of inflammation. Seminars in Immunology, 2015, 27, 161-168.	5.6	115
105	Current Concepts on the Pathogenesis of Type 1 Diabetes—Considerations for Attempts to Prevent and Reverse the Disease. Diabetes Care, 2015, 38, 979-988.	8.6	125
106	NK cells inhibit humoral immunity by reducing the abundance of CD4+ T follicular helper cells during a chronic virus infection. Journal of Leukocyte Biology, 2015, 98, 153-162.	3.3	59
107	Editorial: NK cell reaping of Tfh cells: reckless slaughter or sensible pruning?. Journal of Leukocyte Biology, 2015, 98, 139-142.	3.3	1
108	TRIM33 switches off lfnb1 gene transcription during the late phase of macrophage activation. Nature Communications, 2015, 6, 8900.	12.8	42
109	Differential Inhibition of Macrophage Activation by Lymphocytic Choriomeningitis Virus and Pichinde Virus Is Mediated by the Z Protein N-Terminal Domain. Journal of Virology, 2015, 89, 12513-12517.	3.4	28
110	Superoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage. Immunity, 2015, 43, 974-986.	14.3	50

#	Article	IF	CITATIONS
111	Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use. Cytokine and Growth Factor Reviews, 2015, 26, 121-131.	7.2	43
112	Type I Interferon: Understanding Its Role in HIV Pathogenesis and Therapy. Current HIV/AIDS Reports, 2015, 12, 41-53.	3.1	90
113	T cell exhaustion during persistent viral infections. Virology, 2015, 479-480, 180-193.	2.4	251
114	<scp>HBV</scp> and the immune response. Liver International, 2015, 35, 121-128.	3.9	153
115	Divergent effects of type-I interferons on regulatory T cells. Cytokine and Growth Factor Reviews, 2015, 26, 133-141.	7.2	30
116	Suppression of Fcl <sup>3</sup> -Receptor-Mediated Antibody Effector Function during Persistent Viral Infection. Immunity, 2015, 42, 379-390.	14.3	58
117	Interleukin-1- and Type I Interferon-Dependent Enhanced Immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef Vaccine Vector with Dual Deletions of Type I and Type II Interferon-Binding Proteins. Journal of Virology, 2015, 89, 3819-3832.	3.4	10
118	Type I interferons in infectious disease. Nature Reviews Immunology, 2015, 15, 87-103.	22.7	1,902
119	The Z Proteins of Pathogenic but Not Nonpathogenic Arenaviruses Inhibit RIG-i-Like Receptor-Dependent Interferon Production. Journal of Virology, 2015, 89, 2944-2955.	3.4	112
120	Manipulating IL-10 signalling blockade for better immunotherapy. Cellular Immunology, 2015, 293, 126-129.	3.0	77
121	Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity. Immunity, 2015, 43, 240-250.	14.3	83
122	Cancer Immunity: Lessons From Infectious Diseases. Journal of Infectious Diseases, 2015, 212, S67-S73.	4.0	35
123	The multifaceted biology of plasmacytoid dendritic cells. Nature Reviews Immunology, 2015, 15, 471-485.	22.7	873
124	Interaction between unrelated viruses during in vivo co-infection to limit pathology and immunity. Virology, 2015, 484, 153-162.	2.4	9
125	Modulation of SIV and HIV DNA Vaccine Immunity by Fas-FasL Signaling. Viruses, 2015, 7, 1429-1453.	3.3	3
126	Guarding the frontiers: the biology of type III interferons. Nature Immunology, 2015, 16, 802-809.	14.5	279
127	Molecular and cellular insights into T cell exhaustion. Nature Reviews Immunology, 2015, 15, 486-499.	22.7	3,159
128	A Jekyll and Hyde Profile: Type 1 Interferon Signaling Plays a Prominent Role in the Initiation and Maintenance of a Persistent Virus Infection. Journal of Infectious Diseases, 2015, 212, S31-S36.	4.0	13

Article	IF	CITATIONS
Bone Marrow–Imprinted Gut-Homing of Plasmacytoid Dendritic Cells (pDCs) in Acute Simian Immunodeficiency Virus Infection Results in Massive Accumulation of Hyperfunctional CD4+pDCs in the Mucosae. Journal of Infectious Diseases, 2015, 211, 1717-1725.	4.0	11
Early Virus-Host Interactions Dictate the Course of a Persistent Infection. PLoS Pathogens, 2015, 11, e1004588.	4.7	34
Leukocyte-Derived IFN-α/β and Epithelial IFN-λ Constitute a Compartmentalized Mucosal Defense System that Restricts Enteric Virus Infections. PLoS Pathogens, 2015, 11, e1004782.	4.7	172
Nef, the shuttling molecular adaptor of HIV, influences the cytokine network. Cytokine and Growth Factor Reviews, 2015, 26, 159-173.	7.2	16
Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology, 2015, 149, 190-200.e2.	1.3	222
Disease-Promoting Effects of Type I Interferons in Viral, Bacterial, and Coinfections. Journal of Interferon and Cytokine Research, 2015, 35, 252-264.	1.2	154
Antiviral Effect of Interferon Lambda Against Lymphocytic Choriomeningitis Virus. Journal of Interferon and Cytokine Research, 2015, 35, 540-553.	1.2	10
Blockade of Interferon Beta, but Not Interferon Alpha, Signaling Controls Persistent Viral Infection. Cell Host and Microbe, 2015, 17, 653-661.	11.0	151
IFN-β Selectively Inhibits IL-2 Production through CREM-Mediated Chromatin Remodeling. Journal of Immunology, 2015, 194, 5120-5128.	0.8	7
Overcoming T cell exhaustion in infection and cancer. Trends in Immunology, 2015, 36, 265-276.	6.8	856
New insights into type I interferon and the immunopathogenesis of persistent viral infections. Current Opinion in Immunology, 2015, 34, 91-98.	5.5	37
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature, 2015, 520, 373-377.	27.8	1,955
Interfering with Immunity: Detrimental Role of Type I IFNs during Infection. Journal of Immunology, 2015, 194, 2455-2465.	0.8	72
Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5797-5802.	7.1	90
Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5803-5808.	7.1	118
Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants. Journal of Clinical Investigation, 2015, 125, 2532-2546.	8.2	306
Interferons as Essential Modulators of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1579-1588.	2.4	59

146IFN-α/β Receptor Signaling Promotes Regulatory T Cell Development and Function under Stress0.8Conditions. Journal of Immunology, 2015, 194, 4265-4276.0.8

#

#	Article	IF	Citations
147	Alveolar macrophages and type I IFN in airway homeostasis and immunity. Trends in Immunology, 2015, 36, 307-314.	6.8	87
148	Regulation of antiviral T cell responses by type I interferons. Nature Reviews Immunology, 2015, 15, 231-242.	22.7	371
149	A Ceramide Analogue Stimulates Dendritic Cells To Promote T Cell Responses upon Virus Infections. Journal of Immunology, 2015, 194, 4339-4349.	0.8	25
150	Innate and Adaptive Immune Regulation During Chronic Viral Infections. Annual Review of Virology, 2015, 2, 573-597.	6.7	110
151	No Love Lost Between Viruses and Interferons. Annual Review of Virology, 2015, 2, 549-572.	6.7	123
152	Editorial Commentary: Who is "Special―Now?. Clinical Infectious Diseases, 2015, 61, 826-828.	5.8	0
153	TLR and RLR Signaling Are Reprogrammed in Opposite Directions after Detection of Viral Infection. Journal of Immunology, 2015, 195, 4387-4395.	0.8	31
154	Interferons and the Immunogenic Effects of Cancer Therapy. Trends in Immunology, 2015, 36, 725-737.	6.8	107
155	Human Plasmacytoid Dendritic Cells Elicited Different Responses after Infection with Pathogenic and Nonpathogenic Junin Virus Strains. Journal of Virology, 2015, 89, 7409-7413.	3.4	15
156	A Lymphotoxin/Type I IFN Axis Programs CD8+ T Cells To Infiltrate a Self-Tissue and Propagate Immunopathology. Journal of Immunology, 2015, 195, 4650-4659.	0.8	5
157	Lymphocytic Choriomeningitis Virus Expands a Population of NKG2D+CD8+ T Cells That Exacerbates Disease in Mice Coinfected with <i>Leishmania major</i> . Journal of Immunology, 2015, 195, 3301-3310.	0.8	40
158	The Immune Fulcrum. Progress in Molecular Biology and Translational Science, 2015, 136, 217-243.	1.7	24
159	Infection-induced type I interferons activate CD11b on B-1 cells for subsequent lymph node accumulation. Nature Communications, 2015, 6, 8991.	12.8	60
160	Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C. Gastroenterology, 2015, 149, 25-28.	1.3	16
161	PD-L1 expression is increased in monocyte derived dendritic cells in response to porcine circovirus type 2 and porcine reproductive and respiratory syndrome virus infections. Veterinary Immunology and Immunopathology, 2015, 168, 24-29.	1.2	16
162	Targeting of type I interferon in systemic autoimmune diseases. Translational Research, 2015, 165, 296-305.	5.0	95
163	Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology, 2015, 61, 712-721.	7.3	146
164	NK Cells in T Cell Regulation. , 2016, , 253-261.		0

#	Article	IF	Citations
165	Fighting Chronic Neuroinflammation by Boosting Autoimmunity. , 2016, , 139-148.		0
166	IFN-Î $\mu$ protects primary macrophages against HIV infection. JCI Insight, 2016, 1, e88255.	5.0	30
167	Interferons and HIV Infection: The Good, the Bad, and the Ugly. Pathogens and Immunity, 2016, 1, 107.	3.1	72
168	The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?. Journal of Clinical Investigation, 2016, 127, 103-105.	8.2	29
169	Type I Interferon Impairs Specific Antibody Responses Early during Establishment of LCMV Infection. Frontiers in Immunology, 2016, 7, 564.	4.8	22
170	Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection. Frontiers in Immunology, 2016, 7, 609.	4.8	120
171	Type I IFN Signaling Is Dispensable during Secondary Viral Infection. PLoS Pathogens, 2016, 12, e1005861.	4.7	3
172	CD4 Receptor is a Key Determinant of Divergent HIV-1 Sensing by Plasmacytoid Dendritic Cells. PLoS Pathogens, 2016, 12, e1005553.	4.7	27
173	Transition of T Cells from Effector to Memory Phase. , 2016, , 353-362.		2
174	Hepatitis C virus strategies to evade the specific-T cell response: a possible mission favoring its persistence. Annals of Hepatology, 2016, 15, 17-26.	1.5	10
175	Immune responses and immunopathology in acute and chronic viral hepatitis. Nature Reviews Immunology, 2016, 16, 509-523.	22.7	263
176	Interferon regulatory factor 2 protects mice from lethal viral neuroinvasion. Journal of Experimental Medicine, 2016, 213, 2931-2947.	8.5	12
177	The Impact of Established Immunoregulatory Networks on Vaccine Efficacy and the Development of Immunity to Malaria. Journal of Immunology, 2016, 197, 4518-4526.	0.8	23
178	Measles virus induces persistent infection by autoregulation of viral replication. Scientific Reports, 2016, 6, 37163.	3.3	13
179	The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Science Immunology, 2016, 1, .	11.9	415
180	Too Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy. Immunity, 2016, 45, 1181-1183.	14.3	9
181	Roles of lκB kinase ε in the innate immune defense and beyond. Virologica Sinica, 2016, 31, 457-465.	3.0	15
182	Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity, 2016, 44, 1052-1068.	14.3	213

#	Article	IF	CITATIONS
183	Complex Regulation Pattern of IRF3 Activation Revealed by a Novel Dimerization Reporter System. Journal of Immunology, 2016, 196, 4322-4330.	0.8	25
184	Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling. Cell, 2016, 165, 272-275.	28.9	224
185	HIV-1 Tat Protein Activates both the MyD88 and TRIF Pathways To Induce Tumor Necrosis Factor Alpha and Interleukin-10 in Human Monocytes. Journal of Virology, 2016, 90, 5886-5898.	3.4	43
186	Tumor-necrosis factor is a master of T cell exhaustion. Nature Immunology, 2016, 17, 476-478.	14.5	14
187	Reversing T-cell Dysfunction and Exhaustion in Cancer. Clinical Cancer Research, 2016, 22, 1856-1864.	7.0	317
188	Interferon-Î <sup>3</sup> facilitates hepatic antiviral T cell retention for the maintenance of liver-induced systemic tolerance. Journal of Experimental Medicine, 2016, 213, 1079-1093.	8.5	29
189	Type I Interferons Regulate the Magnitude and Functionality of Mouse Polyomavirus-Specific CD8 T Cells in a Virus Strain-Dependent Manner. Journal of Virology, 2016, 90, 5187-5199.	3.4	18
190	Differential Type I Interferon Signaling Is a Master Regulator of Susceptibility to Postinfluenza Bacterial Superinfection. MBio, 2016, 7, .	4.1	49
191	Differences in Early Cytokine Production Are Associated With Development of a Greater Number of Symptoms Following West Nile Virus Infection. Journal of Infectious Diseases, 2016, 214, 634-643.	4.0	15
192	Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. Journal of Virology, 2016, 90, 8934-8946.	3.4	69
193	Prolonged activation of innate antiviral gene signature after childbirth is determined by <i>IFNL3</i> genotype. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10678-10683.	7.1	22
194	Cell-Cell Sensing of Viral Infection by Plasmacytoid Dendritic Cells. Journal of Virology, 2016, 90, 10050-10053.	3.4	49
195	Type I Interferons Regulate Immune Responses in Humans with Blood-Stage Plasmodium falciparum Infection. Cell Reports, 2016, 17, 399-412.	6.4	88
196	Type I IFN signaling facilitates the development of ILâ€10â€producing effector CD8 <sup>+</sup> T cells during murine influenza virus infection. European Journal of Immunology, 2016, 46, 2778-2788.	2.9	29
197	Immunoactivation induced by chronic viral infection inhibits viral replication and drives immunosuppression through sustained IFN″ responses. European Journal of Immunology, 2016, 46, 372-380.	2.9	20
198	Novel molecular signatures in mononuclear cell populations from patients with systemic lupus erythematosus. Clinical Immunology, 2016, 172, 34-43.	3.2	19
199	Tâ€cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases. Immunology and Cell Biology, 2016, 94, 935-942.	2.3	29
200	Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice. Journal of Virology, 2016, 90, 10102-10112.	3.4	3

#	Article	IF	CITATIONS
201	Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice. Journal of Virology, 2016, 90, 8563-8574.	3.4	22
202	TET3 Inhibits Type I IFN Production Independent of DNA Demethylation. Cell Reports, 2016, 16, 1096-1105.	6.4	40
203	Cross-Regulation of Two Type I Interferon Signaling Pathways in Plasmacytoid Dendritic Cells Controls Anti-malaria Immunity and Host Mortality. Immunity, 2016, 45, 1093-1107.	14.3	100
204	CD169+ macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection. Cell Death and Disease, 2016, 7, e2446-e2446.	6.3	42
206	PTPN22 contributes to exhaustion of T lymphocytes during chronic viral infection. Proceedings of the United States of America, 2016, 113, E7231-E7239.	7.1	38
207	Pleiotropic Roles of Type 1 Interferons in Antiviral Immune Responses. Advances in Immunology, 2016, 132, 135-158.	2.2	21
208	Too much of a good thing: Sustained type 1 interferon signaling limits humoral responses to secondary viral infection. European Journal of Immunology, 2016, 46, 300-302.	2.9	7
209	Sex differences in HIV-1-mediated immunopathology. Current Opinion in HIV and AIDS, 2016, 11, 209-215.	3.8	33
210	Innate Antiviral Defenses Independent of Inducible IFNα/β Production. Trends in Immunology, 2016, 37, 588-596.	6.8	35
211	Cytoplasmic isoforms of Kaposi sarcoma herpesvirus LANA recruit and antagonize the innate immune DNA sensor cGAS. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1034-43.	7.1	128
212	Type I interferons in viral control and immune regulation. Current Opinion in Virology, 2016, 16, 31-40.	5.4	192
213	Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Outcomes. Cell, 2016, 164, 349-352.	28.9	120
214	S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1351-1356.	7.1	50
215	An Odyssey to Viral Pathogenesis. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 1-19.	22.4	2
216	Two separate mechanisms of enforced viral replication balance innate and adaptive immune activation. Journal of Autoimmunity, 2016, 67, 82-89.	6.5	12
217	Resolution of inflammation: a new therapeutic frontier. Nature Reviews Drug Discovery, 2016, 15, 551-567.	46.4	642
218	Type I/II Interferon Balance in the Regulation of Brain Physiology and Pathology. Trends in Immunology, 2016, 37, 181-192.	6.8	104
219	Interferon–microRNA signalling drives liver precancerous lesion formation and hepatocarcinogenesis. Gut, 2016, 65, 1186-1201.	12.1	47

#	Article	IF	CITATIONS
220	Inhibition of Innate Immune Responses Is Key to Pathogenesis by Arenaviruses. Journal of Virology, 2016, 90, 3810-3818.	3.4	43
221	The Anatomy of a Career in Science. DNA and Cell Biology, 2016, 35, 109-117.	1.9	0
222	Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host and Microbe, 2016, 19, 181-193.	11.0	1,284
223	SARS-CoV and IFN: Too Little, Too Late. Cell Host and Microbe, 2016, 19, 139-141.	11.0	90
224	Cytokines and persistent viral infections. Cytokine, 2016, 82, 4-15.	3.2	33
225	Tumor-necrosis factor impairs CD4+ T cell–mediated immunological control in chronic viral infection. Nature Immunology, 2016, 17, 593-603.	14.5	75
226	Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. Cancer Letters, 2016, 381, 259-268.	7.2	30
227	Conditioning of naive CD4+ T cells for enhanced peripheral Foxp3 induction by nonspecific bystander inflammation. Nature Immunology, 2016, 17, 297-303.	14.5	20
228	Apoptotic Epitope–Specific CD8 <sup>+</sup> T Cells and Interferon Signaling Intersect in Chronic Hepatitis C Virus Infection. Journal of Infectious Diseases, 2016, 213, 674-683.	4.0	8
229	Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses. Cellular and Molecular Immunology, 2017, 14, 22-35.	10.5	175
230	Regulation of human intestinal T-cell responses by type 1 interferon-STAT1 signaling is disrupted in inflammatory bowel disease. Mucosal Immunology, 2017, 10, 184-193.	6.0	38
231	Phosphorylation-Dependent Feedback Inhibition of RIG-I by DAPK1 Identified by Kinome-wide siRNA Screening. Molecular Cell, 2017, 65, 403-415.e8.	9.7	40
232	Interleukin 10 inhibits pro-inflammatory cytokine responses and killing of Burkholderia pseudomallei. Scientific Reports, 2017, 7, 42791.	3.3	63
233	Cutting Edge: Fetal/Placental Type I IFN Can Affect Maternal Survival and Fetal Viral Load during Viral Infection. Journal of Immunology, 2017, 198, 3029-3032.	0.8	39
234	Type I interferon-enhanced IL-10 expression in human CD4 T cells is regulated by STAT3, STAT2, and BATF transcription factors. Journal of Leukocyte Biology, 2017, 101, 1181-1190.	3.3	8
235	Type I Interferons Modulate CD8 + T Cell Immunity to mRNA Vaccines. Trends in Molecular Medicine, 2017, 23, 216-226.	6.7	77
236	Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement. Nature Communications, 2017, 8, 14253.	12.8	33
237	Increased Levels of STAT1 Protein in Blood CD4 T Cells from Systemic Lupus Erythematosus Patients Are Associated with Perturbed Homeostasis of Activated CD45RA <sup>-</sup> FOXP3 <sup>hi</sup> Regulatory Subset and Follow-Up Disease Severity. Journal of	1.2	23

#	Article	IF	CITATIONS
238	Coâ€inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunological Reviews, 2017, 276, 9-25.	6.0	13
239	Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity. Journal of Hepatology, 2017, 66, 1130-1137.	3.7	32
240	Type 1 Interferon in the Human Intestine—A Co-ordinator of the Immune Response to the Microbiota. Inflammatory Bowel Diseases, 2017, 23, 524-533.	1.9	23
241	Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4987-4992.	7.1	93
242	Transcriptional and epigenetic regulation of T cell hyporesponsiveness. Journal of Leukocyte Biology, 2017, 102, 601-615.	3.3	39
243	The added value of type I interferons to cytotoxic treatments of cancer. Cytokine and Growth Factor Reviews, 2017, 36, 89-97.	7.2	25
244	Regulation of <scp>CD</scp> 4 T cells and their effects on immunopathological inflammation following viral infection. Immunology, 2017, 152, 328-343.	4.4	16
245	Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets. Journal of Biomedical Science, 2017, 24, 35.	7.0	88
246	The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection. Nature Immunology, 2017, 18, 791-799.	14.5	64
247	Type I Interferon in Chronic Virus Infection and Cancer. Trends in Immunology, 2017, 38, 542-557.	6.8	344
247 248	Type I Interferon in Chronic Virus Infection and Cancer. Trends in Immunology, 2017, 38, 542-557. Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus. Seminars in Liver Disease, 2017, 37, 085-094.	6.8 3.6	344 8
247 248 249	Type I Interferon in Chronic Virus Infection and Cancer. Trends in Immunology, 2017, 38, 542-557.         Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus. Seminars in Liver Disease, 2017, 37, 085-094.         The Transcription Factor T-bet Limits Amplification of Type I IFN Transcriptome and Circuitry in T Helper 1 Cells. Immunity, 2017, 46, 983-991.e4.	6.8 3.6 14.3	344 8 79
247 248 249 250	Type I Interferon in Chronic Virus Infection and Cancer. Trends in Immunology, 2017, 38, 542-557.         Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus. Seminars in Liver Disease, 2017, 37, 085-094.         The Transcription Factor T-bet Limits Amplification of Type I IFN Transcriptome and Circuitry in T Helper 1 Cells. Immunity, 2017, 46, 983-991.e4.         Src family kinases Fyn and Lyn are constitutively activated and mediate plasmacytoid dendritic cell responses. Nature Communications, 2017, 8, 14830.	6.8 3.6 14.3 12.8	<ul> <li>344</li> <li>8</li> <li>79</li> <li>30</li> </ul>
247 248 249 250 251	Type I Interferon in Chronic Virus Infection and Cancer. Trends in Immunology, 2017, 38, 542-557.         Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus. Seminars in Liver Disease, 2017, 37, 085-094.         The Transcription Factor T-bet Limits Amplification of Type I IFN Transcriptome and Circuitry in T Helper 1 Cells. Immunity, 2017, 46, 983-991.e4.         Src family kinases Fyn and Lyn are constitutively activated and mediate plasmacytoid dendritic cell responses. Nature Communications, 2017, 8, 14830.         The viral innate immune antagonism and an alternative vaccine design for PRRS virus. Veterinary Microbiology, 2017, 209, 75-89.	6.8 3.6 14.3 12.8 1.9	<ul> <li>344</li> <li>8</li> <li>79</li> <li>30</li> <li>34</li> </ul>
247 248 249 250 251 252	Type I Interferon in Chronic Virus Infection and Cancer. Trends in Immunology, 2017, 38, 542-557.         Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus. Seminars in Liver Disease, 2017, 37, 085-094.         The Transcription Factor T-bet Limits Amplification of Type I IFN Transcriptome and Circuitry in T Helper 1 Cells. Immunity, 2017, 46, 983-991.e4.         Src family kinases Fyn and Lyn are constitutively activated and mediate plasmacytoid dendritic cell responses. Nature Communications, 2017, 8, 14830.         The viral innate immune antagonism and an alternative vaccine design for PRRS virus. Veterinary Microbiology, 2017, 209, 75-89.         Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review. Journal of Autoimmunity, 2017, 83, 1-11.	<ul> <li>6.8</li> <li>3.6</li> <li>14.3</li> <li>12.8</li> <li>1.9</li> <li>6.5</li> </ul>	<ul> <li>344</li> <li>8</li> <li>79</li> <li>30</li> <li>34</li> <li>213</li> </ul>
247 248 249 250 251 252	Type I Interferon in Chronic Virus Infection and Cancer. Trends in Immunology, 2017, 38, 542-557.         Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus. Seminars in Liver Disease, 2017, 37, 085-094.         The Transcription Factor T-bet Limits Amplification of Type I IFN Transcriptome and Circuitry in T Helper 1 Cells. Immunity, 2017, 46, 983-991.e4.         Src family kinases Fyn and Lyn are constitutively activated and mediate plasmacytoid dendritic cell responses. Nature Communications, 2017, 8, 14830.         The viral innate immune antagonism and an alternative vaccine design for PRRS virus. Veterinary Microbiology, 2017, 209, 75-89.         Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review. Journal of Autoimmunity, 2017, 83, 1-11.         Chronic Type IIFN Is Sufficient To Promote Immunosuppression through Accumulation of Myeloid-Derived Suppressor Cells. Journal of Immunology, 2017, 198, 1156-1163.	<ul> <li>6.8</li> <li>3.6</li> <li>14.3</li> <li>12.8</li> <li>1.9</li> <li>6.5</li> <li>0.8</li> </ul>	<ul> <li>344</li> <li>8</li> <li>79</li> <li>30</li> <li>34</li> <li>213</li> <li>39</li> </ul>
247 248 229 250 251 252 253	Type I Interferon in Chronic Virus Infection and Cancer. Trends in Immunology, 2017, 38, 542-557.         Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus. Seminars in Liver Disease, 2017, 37, 085-094.         The Transcription Factor T-bet Limits Amplification of Type I IFN Transcriptome and Circuitry in T Helper 1 Cells. Immunity, 2017, 46, 983-991.e4.         Src family kinases Fyn and Lyn are constitutively activated and mediate plasmacytoid dendritic cell responses. Nature Communications, 2017, 8, 14830.         The viral innate immune antagonism and an alternative vaccine design for PRRS virus. Veterinary Microbiology, 2017, 209, 75-89.         Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review. Journal of Autoimmunity, 2017, 83, 1-11.         Chronic Type I IFN Is Sufficient To Promote Immunosuppression through Accumulation of Myeloid-Derived Suppressor Cells. Journal of Immunology, 2017, 198, 1156-1163.         FOSL1 Inhibits Type I Interferon Responses to Malaria and Viral Infections by Blocking TBK1 and TRAF3/TRIF Interactions. MBio, 2017, 8, .	<ul> <li>6.8</li> <li>3.6</li> <li>14.3</li> <li>12.8</li> <li>1.9</li> <li>6.5</li> <li>0.8</li> <li>4.1</li> </ul>	<ul> <li>344</li> <li>8</li> <li>79</li> <li>30</li> <li>34</li> <li>213</li> <li>39</li> <li>38</li> </ul>

#	ARTICLE Inflammatory Resolution Triggers a Prolonged Phase of Immune Suppression through	IF	CITATIONS
258	COX-1/mPGES-1-Derived Prostaglandin E 2. Cell Reports, 2017, 20, 3162-3175. B cells require Type 1 interferon to produce alloantibodies to transfused KELâ€expressing red blood cells in mice. Transfusion, 2017, 57, 2595-2608.	1.6	32
259	Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants. Scientific Reports, 2017, 7, 9730.	3.3	35
260	IRF9 Prevents CD8 <sup>+</sup> T Cell Exhaustion in an Extrinsic Manner during Acute Lymphocytic Choriomeningitis Virus Infection. Journal of Virology, 2017, 91, .	3.4	30
261	Humanized Mouse Models for Human Immunodeficiency Virus Infection. Annual Review of Virology, 2017, 4, 393-412.	6.7	65
262	The pros and cons of dying tumour cells in adaptive immune responses. Nature Reviews Immunology, 2017, 17, 591-591.	22.7	17
263	Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon. Journal of Virology, 2017, 91, .	3.4	49
264	Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nature Communications, 2017, 8, 1736.	12.8	304
265	Dichotomous Expression of TNF Superfamily Ligands on Antigen-Presenting Cells Controls Post-priming Anti-viral CD4+ T Cell Immunity. Immunity, 2017, 47, 943-958.e9.	14.3	28
266	Type 1 Diabetes and Type 1 Interferonopathies: Localization of a Type 1 Common Thread of Virus Infection in the Pancreas. EBioMedicine, 2017, 22, 10-17.	6.1	29
267	Irreversible splenic atrophy following chronic LCMV infection is associated with compromised immunity in mice. European Journal of Immunology, 2017, 47, 94-106.	2.9	11
268	Different antiviral effects of IFNα and IFNβ in an HBV mouse model. Immunobiology, 2017, 222, 562-570.	1.9	8
269	Blocking Virus Replication during Acute Murine Cytomegalovirus Infection Paradoxically Prolongs Antigen Presentation and Increases the CD8+ T Cell Response by Preventing Type I IFN–Dependent Depletion of Dendritic Cells. Journal of Immunology, 2017, 198, 383-393.	0.8	10
270	Expression Pattern of Individual <i>IFNA</i> Subtypes in Chronic HIV Infection. Journal of Interferon and Cytokine Research, 2017, 37, 541-549.	1.2	19
271	Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis. Open Forum Infectious Diseases, 2017, 4, ofx067.	0.9	17
272	Resistance of human plasmacytoid dendritic CAL-1 cells to infection with lymphocytic choriomeningitis virus (LCMV) is caused by restricted virus cell entry, which is overcome by contact of CAL-1 cells with LCMV-infected cells. Virology, 2017, 511, 106-113.	2.4	1
273	IFN-β: A Contentious Player in Host–Pathogen Interaction in Tuberculosis. International Journal of Molecular Sciences, 2017, 18, 2725.	4.1	15
274	Protozoan Parasites and Type I IFNs. Frontiers in Immunology, 2017, 8, 14.	4.8	41

#	Article	IF	CITATIONS
275	Murine Cytomegalovirus Disrupts Splenic Dendritic Cell Subsets via Type I Interferon-Dependent and -Independent Mechanisms. Frontiers in Immunology, 2017, 8, 251.	4.8	3
276	The Role of IFN-Î <sup>2</sup> during the Course of Sepsis Progression and Its Therapeutic Potential. Frontiers in Immunology, 2017, 8, 493.	4.8	41
277	Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection. Frontiers in Immunology, 2017, 8, 811.	4.8	10
278	Follicular CD8+ T Cells: Origin, Function and Importance during HIV Infection. Frontiers in Immunology, 2017, 8, 1241.	4.8	32
279	Transcriptome Analysis of Circulating Immune Cell Subsets Highlight the Role of Monocytes in Zaire Ebola Virus Makona Pathogenesis. Frontiers in Immunology, 2017, 8, 1372.	4.8	49
280	The Significance of Type-I Interferons in the Pathogenesis and Therapy of Human Immunodeficiency Virus 1 Infection. Frontiers in Immunology, 2017, 8, 1431.	4.8	23
281	Interferon Lambda Genetics and Biology in Regulation of Viral Control. Frontiers in Immunology, 2017, 8, 1707.	4.8	107
282	Mechanisms underlying plasmacytoid dendritic cell regulation during viral infection. Future Virology, 2017, 12, 403-407.	1.8	0
283	Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients. PLoS ONE, 2017, 12, e0169164.	2.5	5
284	Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C. PLoS ONE, 2017, 12, e0179094.	2.5	1
285	HIV-1 infection depletes human CD34+CD38- hematopoietic progenitor cells via pDC-dependent mechanisms. PLoS Pathogens, 2017, 13, e1006505.	4.7	35
286	Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget, 2017, 8, 71249-71284.	1.8	138
287	Etiology and Pathogenesis of Systemic Lupus Erythematosus. , 2017, , 1329-1344.		7
288	Regulation of autoimmune and antiâ€ŧumour Tâ€cell responses by <scp>PTPN</scp> 22. Immunology, 2018, 154, 377-382.	4.4	33
289	Reduced Chronic Lymphocyte Activation following Interferon Alpha Blockade during the Acute Phase of Simian Immunodeficiency Virus Infection in Rhesus Macaques. Journal of Virology, 2018, 92, .	3.4	23
290	Attenuation of c <scp>GAS</scp> ― <scp>STING</scp> signaling is mediated by a p62/ <scp>SQSTM</scp> lâ€dependent autophagy pathway activated by TBK1. EMBO Journal, 2018, 37, .	7.8	283
291	Who Defends the Stem Cell's Citadel?. Cell Stem Cell, 2018, 22, 287-289.	11.1	1
292	Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection. AIDS Research and Human Retroviruses, 2018, 34, 430-438.	1.1	2

#	Article	IF	CITATIONS
293	Interleukin-27R Signaling Mediates Early Viral Containment and Impacts Innate and Adaptive Immunity after Chronic Lymphocytic Choriomeningitis Virus Infection. Journal of Virology, 2018, 92, .	3.4	26
294	Breaking self-tolerance during autoimmunity and cancer immunity: Myeloid cells and type I IFN response regulation. Journal of Leukocyte Biology, 2018, 103, 1117-1129.	3.3	11
295	microRNA-219 Reduces Viral Load and Pathologic Changes in Theiler's Virus-Induced Demyelinating Disease. Molecular Therapy, 2018, 26, 730-743.	8.2	13
296	CRISPR/Cas9 knockout of USP18 enhances type I IFN responsiveness and restricts HIV-1 infection in macrophages. Journal of Leukocyte Biology, 2018, 103, 1225-1240.	3.3	41
297	Exhaustion and Inflation at Antipodes of T Cell Responses to Chronic Virus Infection. Trends in Microbiology, 2018, 26, 498-509.	7.7	22
298	Exacerbated Apoptosis of Cells Infected with Infectious Bursal Disease Virus upon Exposure to Interferon Alpha. Journal of Virology, 2018, 92, .	3.4	15
299	Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome. Cytokine and Growth Factor Reviews, 2018, 40, 19-31.	7.2	28
300	Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity, 2018, 48, 417-433.	14.3	416
301	Lymphotoxin in physiology of lymphoid tissues – Implication for antiviral defense. Cytokine, 2018, 101, 39-47.	3.2	20
302	Responses to Cytokines and Interferons that Depend upon JAKs and STATs. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028555.	5.5	79
303	Effects of Vaccination with the C-Strain Vaccine on Immune Cells and Cytokines of Pigs Against Classical Swine Fever Virus. Viral Immunology, 2018, 31, 34-39.	1.3	9
304	The diverse functions of the PD1 inhibitory pathway. Nature Reviews Immunology, 2018, 18, 153-167.	22.7	1,210
305	Excessive interferon-α signaling in autoimmunity alters glycosphingolipid processing in B cells. Journal of Autoimmunity, 2018, 89, 53-62.	6.5	4
306	Enhancement of cutaneous immunity during aging by blocking p38 mitogen-activated protein (MAP) kinase–induced inflammation. Journal of Allergy and Clinical Immunology, 2018, 142, 844-856.	2.9	75
307	Nuclear RNF2 inhibits interferon function by promoting K33-linked STAT1 disassociation from DNA. Nature Immunology, 2018, 19, 41-52.	14.5	53
308	The Role of Interferon in Persistent Viral Infection: Insights from Murine Norovirus. Trends in Microbiology, 2018, 26, 510-524.	7.7	41
309	The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics. Journal of Viral Hepatitis, 2019, 26, 4-15.	2.0	12
310	HIV-1 Envelope Glycoproteins Induce the Production of TNF- $\hat{I}$ and IL-10 in Human Monocytes by Activating Calcium Pathway. Scientific Reports, 2018, 8, 17215.	3.3	31

#	Article	IF	CITATIONS
311	High Levels of Eomes Promote Exhaustion of Anti-tumor CD8+ T Cells. Frontiers in Immunology, 2018, 9, 2981.	4.8	137
312	Single-cell RNA sequencing unveils an IL-10-producing helper subset that sustains humoral immunity during persistent infection. Nature Communications, 2018, 9, 5037.	12.8	66
313	The Dual Nature of Type I and Type II Interferons. Frontiers in Immunology, 2018, 9, 2061.	4.8	469
314	Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10. Frontiers in Immunology, 2018, 9, 1923.	4.8	17
315	Detection of host pathways universally inhibited after Plasmodium yoelii infection for immune intervention. Scientific Reports, 2018, 8, 15280.	3.3	15
316	Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferonâ€free treatment era. Immunological Reviews, 2018, 285, 55-71.	6.0	11
317	Fc gamma receptor IIa suppresses type I and III interferon production by human myeloid immune cells. European Journal of Immunology, 2018, 48, 1796-1809.	2.9	17
318	Type I Interferon Signaling Prevents Hepatitis B Virus-Specific T Cell Responses by Reducing Antigen Expression. Journal of Virology, 2018, 92, .	3.4	11
319	Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication. PLoS Pathogens, 2018, 14, e1007246.	4.7	33
320	Long-Term Persistence of Exhausted CD8ÂT Cells in Chronic Infection Is Regulated by MicroRNA-155. Cell Reports, 2018, 23, 2142-2156.	6.4	84
321	Lymphocytic choriomeningitis virus Clone 13 infection causes either persistence or acute death dependent on IFN-1, cytotoxic T lymphocytes (CTLs), and host genetics. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7814-E7823.	7.1	34
322	Ebola Immunity: Gaining a Winning Position in Lightning Chess. Journal of Immunology, 2018, 201, 833-842.	0.8	19
323	Efficacy of a Virus-Like Nanoparticle As Treatment for a Chronic Viral Infection Is Hindered by IRAK1 Regulation and Antibody Interference. Frontiers in Immunology, 2017, 8, 1885.	4.8	3
324	Interferon-α Subtypes As an Adjunct Therapeutic Approach for Human Immunodeficiency Virus Functional Cure. Frontiers in Immunology, 2018, 9, 299.	4.8	23
325	Induction of Type I Interferons by Therapeutic Nanoparticle-Based Vaccination Is Indispensable to Reinforce Cytotoxic CD8+ T Cell Responses During Chronic Retroviral Infection. Frontiers in Immunology, 2018, 9, 614.	4.8	20
326	Lymph Node Cellular and Viral Dynamics in Natural Hosts and Impact for HIV Cure Strategies. Frontiers in Immunology, 2018, 9, 780.	4.8	29
327	The Janus Face of Follicular T Helper Cells in Chronic Viral Infections. Frontiers in Immunology, 2018, 9, 1162.	4.8	19
328	Sustained IFN-I Expression during Established Persistent Viral Infection: A "Bad Seed―for Protective Immunity. Viruses, 2018, 10, 12.	3.3	31

	CITATION	CITATION REPORT	
#	Article	IF	CITATIONS
329	The Biology of Monocytes and Dendritic Cells: Contribution to HIV Pathogenesis. Viruses, 2018, 10, 65.	3.3	51
330	DDX3 suppresses type I interferons and favors viral replication during Arenavirus infection. PLoS Pathogens, 2018, 14, e1007125.	4.7	33
331	Outcome of Antiviral Immunity in the Liver Is Shaped by the Level of Antigen Expressed in Infected Hepatocytes. Hepatology, 2018, 68, 2089-2105.	7.3	9
332	Modeling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with directâ€acting antiviral agents. Immunology and Cell Biology, 2018, 96, 969-980.	2.3	18
333	Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice. Journal of Virology, 2018, 92, .	3.4	41
334	HIV-1 intron-containing RNA expression induces innate immune activation and T cell dysfunction. Nature Communications, 2018, 9, 3450.	12.8	59
335	Cholestasis induced liver pathology results in dysfunctional immune responses after arenavirus infection. Scientific Reports, 2018, 8, 12179.	3.3	7
336	Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment. PLoS Pathogens, 2018, 14, e1006985.	4.7	77
337	Crosstalk between type I and II interferons in regulation of myeloid cell responses during bacterial infection. Current Opinion in Immunology, 2018, 54, 35-41.	5.5	19
338	Immune responses to an early lytic cytomegalovirus antigen in systemic lupus erythematosus patients: T-cell responses, cytokine secretions and antibody status. PLoS ONE, 2018, 13, e0193244.	2.5	5
339	Effects of type I interferons in malaria. Immunology, 2018, 155, 176-185.	4.4	35
340	HIV-1 Infection and Type 1 Interferon: Navigating Through Uncertain Waters. AIDS Research and Human Retroviruses, 2019, 35, 25-32.	1.1	18
341	Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell, 2019, 178, 933-948.e14.	28.9	301
342	Interferon Control of Neurotropic Viral Infections. Trends in Immunology, 2019, 40, 842-856.	6.8	6
343	T Cell Dysfunction in Cancer Immunity and Immunotherapy. Frontiers in Immunology, 2019, 10, 1719.	4.8	219
344	Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection. Cell Reports, 2019, 28, 245-256.e4.	6.4	208
345	The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance. Frontiers in Cellular and Infection Microbiology, 2019, 9, 207.	3.9	194
346	Distinct Roles of Interferon Alpha and Beta in Controlling Chikungunya Virus Replication and Modulating Neutrophil-Mediated Inflammation. Journal of Virology, 2019, 94, .	3.4	49

#	Article	IF	CITATIONS
347	Diverse Immunomodulatory Effects of Individual IFNα Subtypes on Virus-Specific CD8+ T Cell Responses. Frontiers in Immunology, 2019, 10, 2255.	4.8	30
348	Functions and regulation of T cell-derived interleukin-10. Seminars in Immunology, 2019, 44, 101344.	5.6	110
349	USP18 is a significant driver of memory CD4 T-cell reduced viability caused by type I IFN signaling during primary HIV-1 infection. PLoS Pathogens, 2019, 15, e1008060.	4.7	11
350	Lack of Ikaros Deregulates Inflammatory Gene Programs in T Cells. Journal of Immunology, 2019, 202, 1112-1123.	0.8	23
351	Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus. Cells, 2019, 8, 963.	4.1	50
352	Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL. Retrovirology, 2019, 16, 23.	2.0	36
353	Innate immunity limits protective adaptive immune responses against pre-erythrocytic malaria parasites. Nature Communications, 2019, 10, 3950.	12.8	34
354	Defining â€~T cell exhaustion'. Nature Reviews Immunology, 2019, 19, 665-674.	22.7	879
355	CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annual Review of Immunology, 2019, 37, 457-495.	21.8	1,143
356	Type I Interferon Receptor on NK Cells Negatively Regulates Interferon-Î <sup>3</sup> Production. Frontiers in Immunology, 2019, 10, 1261.	4.8	19
357	Type I interferon signaling, regulation and gene stimulation in chronic virus infection. Seminars in Immunology, 2019, 43, 101277.	5.6	62
358	IL-27 promotes the expansion of self-renewing CD8+ T cells in persistent viral infection. Journal of Experimental Medicine, 2019, 216, 1791-1808.	8.5	45
359	Pathogenic Role of Type I Interferons in HIV-Induced Immune Impairments in Humanized Mice. Current HIV/AIDS Reports, 2019, 16, 224-229.	3.1	11
360	CD8+ T cell exhaustion. Seminars in Immunopathology, 2019, 41, 327-337.	6.1	169
361	IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation. Immunity, 2019, 50, 871-891.	14.3	603
362	Shared and Distinct Functions of Type I and Type III Interferons. Immunity, 2019, 50, 907-923.	14.3	699
363	From Bench to Bedside: Evaluation of AHCC Supplementation to Modulate the Host Immunity to Clear High-Risk Human Papillomavirus Infections. Frontiers in Oncology, 2019, 9, 173.	2.8	18
364	Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nature Cell Biology, 2019, 21, 511-521.	10.3	121

#	Article	IF	CITATIONS
365	Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors. Frontiers in Immunology, 2019, 10, 372.	4.8	57
366	Regulators of Tâ€cell fate: Integration of cell migration, differentiation and function. Immunological Reviews, 2019, 289, 101-114.	6.0	47
367	NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nature Communications, 2019, 10, 1507.	12.8	109
368	Complexities of Type I Interferon Biology: Lessons from LCMV. Viruses, 2019, 11, 172.	3.3	22
369	TLR4 signaling improves PD-1 blockade therapy during chronic viral infection. PLoS Pathogens, 2019, 15, e1007583.	4.7	17
370	The role of type I interferons in CD4+ T cell differentiation. Immunology Letters, 2019, 215, 19-23.	2.5	29
371	Molecular Basis of the Differentiation and Function of Virus Specific Follicular Helper CD4+ T Cells. Frontiers in Immunology, 2019, 10, 249.	4.8	21
372	Sustained Type I Interferon Reinforces NK Cell–Mediated Cancer Immunosurveillance during Chronic Virus Infection. Cancer Immunology Research, 2019, 7, 584-599.	3.4	27
373	The ubiquitin-like modifier FAT10 is required for normal IFN-Î <sup>3</sup> production by activated CD8+ T cells. Molecular Immunology, 2019, 108, 111-120.	2.2	13
374	Is Resolution the End of Inflammation?. Trends in Molecular Medicine, 2019, 25, 198-214.	6.7	131
375	Immune Exhaustion: Past Lessons and New Insights from Lymphocytic Choriomeningitis Virus. Viruses, 2019, 11, 156.	3.3	32
376	Manipulating the Interferon Signaling Pathway: Implications for HIV Infection. Virologica Sinica, 2019, 34, 192-196.	3.0	13
377	A dynamical motif comprising the interactions between antigens and CD8 T cells may underlie the outcomes of viral infections. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17393-17398.	7.1	33
378	The uric acid crystal receptor Clec12A potentiates type I interferon responses. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 18544-18549.	7.1	31
379	Type III IFNs: Beyond antiviral protection. Seminars in Immunology, 2019, 43, 101303.	5.6	66
380	PD-1 Signaling Promotes Control of Chronic Viral Infection by Restricting Type-I-Interferon-Mediated Tissue Damage. Cell Reports, 2019, 29, 2556-2564.e3.	6.4	6
381	PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nature Immunology, 2019, 20, 1335-1347.	14.5	142
382	Mechanisms of lymphatic system-specific viral replication and its potential role in autoimmune disease. Clinical and Experimental Immunology, 2018, 195, 64-73.	2.6	7

		CITATION REPORT		
#	Article		IF	CITATIONS
383	AISF position paper on HCV in immunocompromised patients. Digestive and Liver Disease, 20	19, 51, 10-23.	0.9	5
384	Type I interferons differentially modulate maternal host immunity to infection by <i>Listeria monocytogenes</i> and <i>Salmonella enterica</i> serovar Typhimurium during pregnancy. A Journal of Reproductive Immunology, 2019, 81, e13068.	merican	1.2	8
385	Type I Interferons in Autoimmune Disease. Annual Review of Pathology: Mechanisms of Disea 369-393.	se, 2019, 14,	22.4	179
386	Modulation of immune responses in lentiviral vector-mediated gene transfer. Cellular Immunc 2019, 342, 103802.	logy,	3.0	49
387	Tumour-intrinsic resistance to immune checkpoint blockade. Nature Reviews Immunology, 20 25-39.	20, 20,	22.7	856
388	Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resi Seminars in Cancer Biology, 2020, 65, 114-122.	stance.	9.6	45
389	The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19. Frontiers in Im 2020, 11, 595739.	.munology,	4.8	90
390	Innate immunity and alpha/gammaherpesviruses: first impressions last a lifetime. Current Opi Virology, 2020, 44, 81-89.	nion in	5.4	5
391	MDA5 Is an Essential Sensor of a Pathogen-Associated Molecular Pattern Associated with Vita Is Necessary for Host Resistance against <i>Aspergillus fumigatus</i> . Journal of Immunology 205, 3058-3070.	llity That , 2020,	0.8	16
392	Tumor Fibroblast–Derived FGF2 Regulates Expression of SPRY1 in Esophageal Tumor–Infi Cells and Plays a Role in T-cell Exhaustion. Cancer Research, 2020, 80, 5583-5596.	trating T	0.9	22
393	Type I interferon signaling limits viral vector priming of CD8 + T cells during initiation of vitilig melanoma immunotherapy. Pigment Cell and Melanoma Research, 2020, 34, 683-695.	o and	3.3	6
394	Type I Interferons Ameliorate Zinc Intoxication of Candida glabrata by Macrophages and Prom Fungal Immune Evasion. IScience, 2020, 23, 101121.	iote	4.1	14
395	Tau Pathology Drives Dementia Risk-Associated Gene Networks toward Chronic Inflammatory and Immunosuppression. Cell Reports, 2020, 33, 108398.	States	6.4	57
396	Cytokine Storm May Not Be the Chief Culprit for the Deterioration of COVID-19. Viral Immuno 2020, 34, 336-341.	blogy,	1.3	10
397	Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes. Frontiers in Immunology, 578877.	2020, 11,	4.8	76
398	Type I Interferons and Malaria: A Double-Edge Sword Against a Complex Parasitic Disease. Fro Cellular and Infection Microbiology, 2020, 10, 594621.	ntiers in	3.9	29
399	Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease. Frontiers in Im 2020, 11, 606874.	munology,	4.8	18
400	Distinct Molecular Mechanisms of Host Immune Response Modulation by Arenavirus NP and 2 Proteins. Viruses, 2020, 12, 784.	2	3.3	8

#	Article	IF	CITATIONS
401	Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virusâ€specific CD8 + T cells after directâ€acting antiviral therapies. Journal of Viral Hepatitis, 2020, 27, 1408-1418.	2.0	4
402	Early type I IFN blockade improves the efficacy of viral vaccines. Journal of Experimental Medicine, 2020, 217, .	8.5	38
403	The transcription factor NFAT5 limits infection-induced type I interferon responses. Journal of Experimental Medicine, 2020, 217, .	8.5	14
404	A network of immune and microbial modifications underlies viral persistence in the gastrointestinal tract. Journal of Experimental Medicine, 2020, 217, .	8.5	6
405	Type I IFNs and CD8 T cells increase intestinal barrier permeability after chronic viral infection. Journal of Experimental Medicine, 2020, 217, .	8.5	28
406	Immunomodulation Induced During Interferon-α Therapy Impairs the Anti-HBV Immune Response Through CD24+CD38hi B Cells. Frontiers in Immunology, 2020, 11, 591269.	4.8	11
407	Loss of Resistance to Mousepox during Chronic Lymphocytic Choriomeningitis Virus Infection Is Associated with Impaired T-Cell Responses and Can Be Rescued by Immunization. Journal of Virology, 2020, 94, .	3.4	1
408	Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial. Journal of Inflammation, 2020, 17, 19.	3.4	7
409	Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science, 2020, 369, 712-717.	12.6	333
410	The Role of Type I IFNs in Influenza: Antiviral Superheroes or Immunopathogenic Villains?. Journal of Innate Immunity, 2020, 12, 437-447.	3.8	46
411	Integrating context of tumor biology and vaccine design to shape multidimensional immunotherapies. Future Drug Discovery, 2020, 2, FDD25.	2.1	1
412	Deletion of the Gene for the Type I Interferon Inhibitor 1329L from the Attenuated African Swine Fever Virus OURT88/3 Strain Reduces Protection Induced in Pigs. Vaccines, 2020, 8, 262.	4.4	23
413	Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. International Journal of Medical Sciences, 2020, 17, 892-902.	2.5	28
414	Infectious Diseases and the Lymphoid Extracellular Matrix Remodeling: A Focus on Conduit System. Cells, 2020, 9, 725.	4.1	14
415	Circadian control of interferon-sensitive gene expression in murine skin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5761-5771.	7.1	38
416	A Dual Role of Type I Interferons in Antitumor Immunity. Advanced Biology, 2020, 4, e1900237.	3.0	23
417	C-Type Lectin-Like Receptors: Head or Tail in Cell Death Immunity. Frontiers in Immunology, 2020, 11, 251.	4.8	68
418	TLR4 abrogates the Th1 immune response through IRF1 and IFN-β to prevent immunopathology during L. infantum infection. PLoS Pathogens, 2020, 16, e1008435.	4.7	16

#	Article	IF	CITATIONS
419	Chronic virus infection drives CD8 T cell-mediated thymic destruction and impaired negative selection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5420-5429.	7.1	23
420	Transcriptional insights into the CD8+ T cell response in mono-HIV and HCV infection. Journal of Translational Medicine, 2020, 18, 96.	4.4	4
421	A dual role for hepatocyte-intrinsic canonical NF-κB signalingÂinÂvirus control. Journal of Hepatology, 2020, 72, 960-975.	3.7	18
422	A mouse model of MSU-induced acute inflammation <i>in vivo</i> suggests imiquimod-dependent targeting of <i>II-1β</i> as relevant therapy for gout patients. Theranostics, 2020, 10, 2158-2171.	10.0	28
423	EGF receptor inhibitors comprehensively suppress hepatitis B virus by downregulation of STAT3 phosphorylation. Biochemistry and Biophysics Reports, 2020, 22, 100763.	1.3	12
424	Dysregulation of humoral immunity in chronic infection. Immunology and Cell Biology, 2020, 98, 456-466.	2.3	14
425	On the impact of hepatitis C virus and heterologous immunity on alloimmune responses following liver transplantation. American Journal of Transplantation, 2021, 21, 247-257.	4.7	8
426	Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy. Cancer Letters, 2021, 499, 279-289.	7.2	7
427	Opposing Roles of Type I Interferons in Cancer Immunity. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 167-198.	22.4	88
428	Parallels Between the Antiviral State and the Irradiated State. Journal of the National Cancer Institute, 2021, 113, 969-979.	6.3	4
429	Frontline Science: Estrogen-related receptor Î <sup>3</sup> increases poly(I:C)-mediated type I IFN expression in mouse macrophages. Journal of Leukocyte Biology, 2021, 109, 865-875.	3.3	5
430	Role of CD4+ T Cells in the Control of Viral Infections: Recent Advances and Open Questions. International Journal of Molecular Sciences, 2021, 22, 523.	4.1	28
431	The myeloid cell type I IFN system promotes antitumor immunity over proâ€ŧumoral inflammation in cancer Tâ€cell therapy. Clinical and Translational Immunology, 2021, 10, e1276.	3.8	5
432	Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge. Vaccine, 2021, 39, 1257-1264.	3.8	2
433	TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense. Viruses, 2021, 13, 279.	3.3	18
434	Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity. Frontiers in Immunology, 2020, 11, 620283.	4.8	2
435	Type I interferons affect the metabolic fitness of CD8+ T cells from patients with systemic lupus erythematosus. Nature Communications, 2021, 12, 1980.	12.8	56
436	IFNAR1 signaling in NK cells promotes persistent virus infection. Science Advances, 2021, 7, .	10.3	10

#	Article	IF	CITATIONS
437	Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. Nature Communications, 2021, 12, 1858.	12.8	47
438	Aging and Interferons: Impacts on Inflammation and Viral Disease Outcomes. Cells, 2021, 10, 708.	4.1	32
439	Opposing effects of T cell receptor signal strength on CD4 T cells responding to acute versus chronic viral infection. ELife, 2021, 10, .	6.0	19
440	Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy. Cancer Discovery, 2021, 11, 2186-2199.	9.4	85
441	Slow viral propagation during initial phase of infection leads to viral persistence in mice. Communications Biology, 2021, 4, 508.	4.4	6
443	Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation. Trends in Immunology, 2021, 42, 312-322.	6.8	86
445	Interferon regulatory factor 7 impairs cellular metabolism with age in adipose-derived stromal cells. Journal of Cell Science, 2021, 134, .	2.0	5
446	A sustained type I IFN-neutrophil-IL-18 axis drives pathology during mucosal viral infection. ELife, 2021, 10, .	6.0	15
447	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood, 2021, 137, 2621-2633.	1.4	137
448	DHX15 is required to control RNA virus-induced intestinal inflammation. Cell Reports, 2021, 35, 109205.	6.4	28
450	Immune evasion by cancer stem cells. Regenerative Therapy, 2021, 17, 20-33.	3.0	63
451	Mechanisms of Immune Modulation by Radiation. Seminars in Radiation Oncology, 2021, 31, 205-216.	2.2	5
452	Sex Differences in Primary HIV Infection: Revisiting the Role of TLR7-Driven Type 1 IFN Production by Plasmacytoid Dendritic Cells in Women. Frontiers in Immunology, 2021, 12, 729233.	4.8	13
453	Robust innate immune responses at the placenta during early gestation may limit in utero HIV transmission. PLoS Pathogens, 2021, 17, e1009860.	4.7	7
455	Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?. Biology, 2021, 10, 913.	2.8	2
456	Type I Interferon Induction and Exhaustion during Viral Infection: Plasmacytoid Dendritic Cells and Emerging COVID-19 Findings. Viruses, 2021, 13, 1839.	3.3	21
457	Type I Interferon Promotes Humoral Immunity in Viral Vector Vaccination. Journal of Virology, 2021, 95, e0092521.	3.4	9
458	Resolving inflammation. Nature Reviews Immunology, 2021, 21, 620-621.	22.7	3

#	Article	IF	CITATIONS
460	Simultaneous or prior activation of intrahepatic type I interferon signaling leads to hepatitis B virus persistence in a mouse model. Journal of Virology, 2021, 95, e0003421.	3.4	3
461	A TLR7 antagonist restricts interferon-dependent and -independent immunopathology in a mouse model of severe influenza. Journal of Experimental Medicine, 2021, 218, .	8.5	10
462	Dysregulation of immune gene expression profiles during HTLV-1 infection. Meta Gene, 2021, 30, 100944.	0.6	0
463	Interferons. , 2021, , 447-452.		2
464	Integrin Alpha E (CD103) Limits Virus-Induced IFN-I Production in Conventional Dendritic Cells. Frontiers in Immunology, 2020, 11, 607889.	4.8	1
465	Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2–reactive CD8 <sup>+</sup> T cells. Science Immunology, 2021, 6, .	11.9	185
466	The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies. Antiviral Research, 2020, 174, 104702.	4.1	16
477	Type I interferon suppresses virus-specific B cell responses by modulating CD8 <sup>+</sup> T cell differentiation. Science Immunology, 2016, 1, .	11.9	80
478	Interferon-driven deletion of antiviral B cells at the onset of chronic infection. Science Immunology, 2016, 1, .	11.9	90
479	TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women. JCI Insight, 2020, 5, .	5.0	36
480	Type I interferons suppress viral replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection. JCI Insight, 2017, 2, .	5.0	83
481	Sphingosine kinase 2 restricts T cell immunopathology but permits viral persistence. Journal of Clinical Investigation, 2020, 130, 6523-6538.	8.2	17
482	IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. Journal of Clinical Investigation, 2019, 129, 3625-3639.	8.2	460
483	Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. Journal of Clinical Investigation, 2013, 123, 4859-4874.	8.2	138
484	Type I IFN signaling in CD8– DCs impairs Th1-dependent malaria immunity. Journal of Clinical Investigation, 2014, 124, 2483-2496.	8.2	96
485	Plasmacytoid dendritic cells promote HIV-1–induced group 3 innate lymphoid cell depletion. Journal of Clinical Investigation, 2015, 125, 3692-3703.	8.2	66
486	Targeting type l interferon–mediated activation restores immune function in chronic HIV infection. Journal of Clinical Investigation, 2016, 127, 260-268.	8.2	153
487	Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. Journal of Clinical Investigation, 2016, 127, 269-279.	8.2	151

#	Article	IF	CITATIONS
488	HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells. Journal of Clinical Investigation, 2017, 127, 4352-4364.	8.2	17
489	HIV and innate immunity – a genomics perspective. F1000prime Reports, 2013, 5, 29.	5.9	10
490	A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. PLoS Neglected Tropical Diseases, 2017, 11, e0005908.	3.0	76
491	Targeted Deletion of FGL2 Leads to Increased Early Viral Replication and Enhanced Adaptive Immunity in a Murine Model of Acute Viral Hepatitis Caused by LCMV WE. PLoS ONE, 2013, 8, e72309.	2.5	19
492	Major and Minor Group Rhinoviruses Elicit Differential Signaling and Cytokine Responses as a Function of Receptor-Mediated Signal Transduction. PLoS ONE, 2014, 9, e93897.	2.5	26
493	CD8+ T Cells Specific to Apoptosis-Associated Antigens Predict the Response to Tumor Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0128607.	2.5	19
494	Type I and Type II Interferon Coordinately Regulate Suppressive Dendritic Cell Fate and Function during Viral Persistence. PLoS Pathogens, 2016, 12, e1005356.	4.7	49
495	Type I Interferon Receptor Deficiency in Dendritic Cells Facilitates Systemic Murine Norovirus Persistence Despite Enhanced Adaptive Immunity. PLoS Pathogens, 2016, 12, e1005684.	4.7	56
496	Type I Interferons Induce T Regulatory 1 Responses and Restrict Humoral Immunity during Experimental Malaria. PLoS Pathogens, 2016, 12, e1005945.	4.7	62
497	Cytomegalovirus-Specific IL-10-Producing CD4+ T Cells Are Governed by Type-I IFN-Induced IL-27 and Promote Virus Persistence. PLoS Pathogens, 2016, 12, e1006050.	4.7	46
498	Pegivirus avoids immune recognition but does not attenuate acute-phase disease in a macaque model of HIV infection. PLoS Pathogens, 2017, 13, e1006692.	4.7	15
499	Qualitative Differences Between the IFNα subtypes and IFNβ Influence Chronic Mucosal HIV-1 Pathogenesis. PLoS Pathogens, 2020, 16, e1008986.	4.7	22
500	Cognitive Consequences of a Sustained Monocyte Type 1 IFN Response in HIV-1 Infection. Current HIV Research, 2014, 12, 77-84.	0.5	21
501	Viruses Teaching Immunology: Role of LCMV Model and Human Viral Infections in Immunological Discoveries. Viruses, 2019, 11, 106.	3.3	16
502	"Toll-free―pathways for production of type I interferons. AIMS Allergy and Immunology, 2017, 1, 143-163.	0.5	9
503	Interim Guidelines on Antiviral Therapy for COVID-19. Infection and Chemotherapy, 2020, 52, 281.	2.3	29
504	The viral context instructs the redundancy of costimulatory pathways in driving CD8+ T cell expansion. ELife, 2015, 4, .	6.0	48
505	AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity. ELife, 2016, 5, .	6.0	54

		CHATION REPORT	
#	ARTICLE	IF	CITATIONS
506	Type I interferon underlies severe disease associated with JunAn virus infection in mice. ELife, 2020, 9, .	6.0	8
507	Chronic LCMV Infection Is Fortified with Versatile Tactics to Suppress Host T Cell Immunity and Establish Viral Persistence. Viruses, 2021, 13, 1951.	3.3	3
508	Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice. Science Translational Medicine, 2021, 13, eaba6006.	12.4	33
509	Type I interferon supports γδTâ€cell homeostasis and immunity through direct and indirect receptor signaling in mice. European Journal of Immunology, 2021, 51, 3186-3193.	2.9	1
510	The interplay of immunology and cachexia in infection and cancer. Nature Reviews Immunology, 2022, 22, 309-321.	22.7	69
512	HIV-Associated Immune Exhaustion. , 2014, , 1-8.		0
513	Type I Interferons in Immune Defense Against Streptococci. , 2014, , 43-59.		0
515	Innate Immune Recognition of Hepatitis C Virus. , 2016, , 299-329.		0
516	Innate Cytokine Responses and Their Functions during Viral Infections. , 2016, , 222-234.		0
519	HIV-Associated Immune Exhaustion. , 2018, , 1001-1008.		0
520	The Pathophysiology of Arthritis Due to Viruses and Vaccines. , 2019, , 91-106.		0
523	Chronic viral infections persistently alter marrow stroma and impair hematopoietic stem cell fitness. Journal of Experimental Medicine, 2021, 218, .	8.5	27
527	Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer. World Journal of Gastrointestinal Oncology, 2020, 12, 1216-1236.	2.0	1
530	Identification of Candidate Predictors of Lupus Flare. Transactions of the American Clinical and Climatological Association, 2015, 126, 184-96.	0.5	1
532	The pathogenic role of IFN- $\hat{l}\pm$ in thyroiditis mouse models. Life Sciences, 2022, 288, 120172.	4.3	2
533	Interferon Alpha, but Not Interferon Beta, Acts Early To Control Chronic Chikungunya Virus Pathogenesis. Journal of Virology, 2022, 96, JVI0114321.	3.4	4
534	Targeting BMI-1 in B cells restores effective humoral immune responses and controls chronic viral infection. Nature Immunology, 2022, 23, 86-98.	14.5	17
535	Epidemiologic, Clinical and Immunological Consequences of Co-Infections during Canine Leishmaniosis. Animals, 2021, 11, 3206.	2.3	5

#	Article	IF	CITATIONS
536	Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection. Nature Immunology, 2021, 22, 1524-1537.	14.5	26
537	In vivo genome-wide CRISPR screens identify SOCS1 as intrinsic checkpoint of CD4 <sup>+</sup> T <sub>H</sub> 1 cell response. Science Immunology, 2021, 6, eabe8219.	11.9	32
538	Type I interferons: One stone to concurrently kill two birds, viral infections and cancers. Current Research in Virological Science, 2021, 2, 100014.	3.5	5
539	Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors. Viruses, 2022, 14, 118.	3.3	14
540	IL-33 Coordinates Innate Defense to Systemic Candida albicans Infection by Regulating IL-23 and IL-10 in an Opposite Way. Journal of Immunology, 2022, 208, 660-671.	0.8	2
542	B cell–derived IL-27 promotes control of persistent LCMV infection. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	13
543	Immune Profiling of COVID-19 in Correlation with SARS and MERS. Viruses, 2022, 14, 164.	3.3	11
544	Immunotherapy With Interferon α11, But Not Interferon Beta, Controls Persistent Retroviral Infection. Frontiers in Immunology, 2021, 12, 809774.	4.8	4
545	Induction of thymic atrophy and loss of thymic output by type-I interferons during chronic viral infection. Virology, 2022, 567, 77-86.	2.4	2
546	IFN-α blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health. JCI Insight, 2022, 7, .	5.0	6
547	Interferon-β acts directly on TÂcells to prolong allograft survival by enhancing regulatory T cell induction through Foxp3 acetylation. Immunity, 2022, 55, 459-474.e7.	14.3	17
548	Chronic Type I Interferons Signaling Promotes Lipid Peroxidation-Driven Terminal CD8 <sup>+</sup> T Cell Exhaustion and Curtails Anti-PD-1 Treatment Efficacy. SSRN Electronic Journal, 0, , .	0.4	0
550	Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nature Immunology, 2022, 23, 632-642.	14.5	54
551	STING Agonists/Antagonists: Their Potential as Therapeutics and Future Developments. Cells, 2022, 11, 1159.	4.1	21
552	Caspase-8 has dual roles in regulatory T cell homeostasis balancing immunity to infection and collateral inflammatory damage. Science Immunology, 2022, 7, eabn8041.	11.9	8
553	Expression of Id3 represses exhaustion of anti-tumor CD8 T cells in liver cancer. Molecular Immunology, 2022, 144, 117-126.	2.2	5
570	Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus. Nature Reviews Endocrinology, 2022, 18, 503-516.	9.6	55
571	Identifying enhancers of innate immune signaling as broad-spectrum antivirals active against emerging viruses. Cell Chemical Biology, 2022, 29, 1113-1125.e6.	5.2	10

#	Article	IF	CITATIONS
572	AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections. Frontiers in Oncology, 0, 12, .	2.8	11
574	Autoreactive CD8 T cells in NOD mice exhibit phenotypic heterogeneity but restricted TCR gene usage. Life Science Alliance, 2022, 5, e202201503.	2.8	2
575	Type I Interferons Promote Germinal Centers Through B Cell Intrinsic Signaling and Dendritic Cell Dependent Th1 and Tfh Cell Lineages. Frontiers in Immunology, 0, 13, .	4.8	9
578	Interplay between innate immunity and the viral oncoproteins Tax and HBZ in the pathogenesis and therapeutic response of HTLV-1 associated adult T cell leukemia. Frontiers in Immunology, 0, 13, .	4.8	6
579	Exposing the Two Contrasting Faces of STAT2 in Inflammation. Journal of Interferon and Cytokine Research, 2022, 42, 467-481.	1.2	3
580	Comparison of demographic features and laboratory parameters between COVID-19 deceased patients and surviving severe and critically ill cases. World Journal of Clinical Cases, 2022, 10, 8161-8169.	0.8	4
581	HIV-1 induction of tolerogenic dendritic cells is mediated by cellular interaction with suppressive T cells. Frontiers in Immunology, 0, 13, .	4.8	3
582	Temporally restricted activation of IFN $\hat{l}^2$ signaling underlies response to immune checkpoint therapy in mice. Nature Communications, 2022, 13, .	12.8	12
583	Synthetic mimetics assigned a major role to IFNAR2 in type I interferon signaling. Frontiers in Microbiology, 0, 13, .	3.5	3
584	Splicing factor SRSF1 is essential for CD8 T cell function and host antigen-specific viral immunity. Frontiers in Immunology, 0, 13, .	4.8	1
585	<scp>CD8</scp> <sup>+</sup> T cell exhaustion in antiâ€ŧumour immunity: The new insights for cancer immunotherapy. Immunology, 2023, 168, 30-48.	4.4	20
586	Control of Simian Immunodeficiency Virus Infection in Prophylactically Vaccinated, Antiretroviral Treatment-Naive Macaques Is Required for the Most Efficacious CD8 T Cell Response during Treatment with the Interleukin-15 Superagonist N-803. Journal of Virology, 2022, 96, .	3.4	6
587	Delineating the transcriptional landscape and clonal diversity of virus-specific CD4+ T cells during chronic viral infection. ELife, 0, 11, .	6.0	9
588	Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti- <i>Toxoplasma</i> Immunity. MBio, 2022, 13, .	4.1	7
589	SARS oVâ€2, HIV, and HPV: Convergent evolution of selective regulation of cGAS–STING signaling. Journal of Medical Virology, 2023, 95, .	5.0	4
591	Clonal lineage tracing reveals mechanisms skewing CD8+ T cell fate decisions in chronic infection. Journal of Experimental Medicine, 2023, 220, .	8.5	27
592	Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ TÂcell exhaustion and curtails anti-PD-1 efficacy. Cell Reports, 2022, 41, 111647.	6.4	12
594	Inflammatory platelet production stimulated by tyrosyl-tRNA synthetase mimicking viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	2

		CITATION REPORT		
#	Article		IF	CITATIONS
595	CD8+ T cell exhaustion and cancer immunotherapy. Cancer Letters, 2023, 559, 216043.		7.2	18
596	<scp>EGFR</scp> inhibition in <scp>EGFR</scp> â€mutant lung cancer cells perturbs in signaling pathways in the tumor microenvironment. Cancer Science, 2023, 114, 1270-12	nate immune 283.	3.9	5
597	Ablation of Adar1 in myeloid cells imprints a global antiviral state in the lung and heighte immunity against SARS-CoV-2. Cell Reports, 2023, 42, 112038.	ns early	6.4	1
598	Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epig memory to sustain T cell dysfunction. Nature Cancer, 0, , .	genetic	13.2	10
599	Early transcriptional and epigenetic divergence of CD8+ T cells responding to acute versi infection. PLoS Biology, 2023, 21, e3001983.	us chronic	5.6	8
600	The Complexity of Interferon Signaling in Host Defense against Protozoan Parasite Infec Pathogens, 2023, 12, 319.	tion.	2.8	3
602	The alarmin interleukin-33 promotes the expansion and preserves the stemness of Tcf-1- chronic viral infection. Immunity, 2023, 56, 813-828.e10.	- CD8+ TÂcells in	14.3	12
603	A necroptosis-independent function of RIPK3 promotes immune dysfunction and preven chronic LCMV infection. Cell Death and Disease, 2023, 14, .	ts control of	6.3	3
604	Interleukin-3 protects against viral pneumonia in sepsis by enhancing plasmacytoid denc recruitment into the lungs and T cell priming. Frontiers in Immunology, 0, 14, .	lritic cell	4.8	2
605	Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury. Jou Hepatology, 2023, 79, 150-166.	rnal of	3.7	6
607	A single-cell atlas reveals shared and distinct immune responses and metabolic profiles ir and HIV-1 infections. Frontiers in Genetics, 0, 14, .	า SARS-CoV-2	2.3	1
608	DNA sensing via the cGAS/STING pathway activates the immunoproteasome and adaptiv EMBO Journal, 2023, 42, .	re T ell immunity.	7.8	3
609	Potential Therapeutic Value of the STING Inhibitors. Molecules, 2023, 28, 3127.		3.8	5
610	CISH impairs lysosomal function in activated T cells resulting in mitochondrial DNA relea inflammaging. Nature Aging, 2023, 3, 600-616.	se and	11.6	4
611	In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy resp cancer. Nature Communications, 2023, 14, .	onse in lung	12.8	6
612	Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell Dysfunction. Cancer Discovery, 2023, 13, 1636-1655.	–Intrinsic	9.4	4
613	IL-3 orchestrates ulcerative colitis pathogenesis by controlling the development and the of splenic reservoir neutrophils. Cell Reports, 2023, 42, 112637.	recruitment	6.4	2
614	Loss of PBAF promotes expansion and effector differentiation of CD8+ TÂcells during ch infection and cancer. Cell Reports, 2023, 42, 112649.	ronic viral	6.4	4

#	Article	IF	Citations
615	Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade. Frontiers in Immunology, 0, 14, .	4.8	2
617	Heterogeneity and functions of the 13 IFNâ€Î± subtypes – lucky for some?. European Journal of Immunology, 2023, 53, .	2.9	2
618	Mutant p53 leads to lowâ€grade IFNâ€lâ€induced inflammation and impairs cGAS–STING signalling in mice. European Journal of Immunology, 2023, 53, .	2.9	1
620	Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective. Experimental and Molecular Medicine, 2023, 55, 1333-1347.	7.7	5
621	IL-6 and IL-27 play both distinct and redundant roles in regulating CD4 T-cell responses during chronic viral infection. Frontiers in Immunology, 0, 14, .	4.8	0
622	Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen. Emerging Microbes and Infections, 2023, 12, .	6.5	0
623	Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development. Diagnostics, 2023, 13, 2708.	2.6	1
624	Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ TÂcell exhaustion via TRIM14-IFN-β axis. Cell Reports, 2023, 42, 112944.	6.4	0
625	Cellular and molecular waypoints along the path of T cell exhaustion. Science Immunology, 2023, 8, .	11.9	5
626	Protective versus Pathogenic Type I Interferon Responses during Virus Infections. Viruses, 2023, 15, 1916.	3.3	0
627	Serum levels of type I interferon (IFN-I) is associated with the severity of COVID-19. Journal of Medical Microbiology, 2023, 72, .	1.8	2
628	Diverse roles of lung macrophages in the immune response to influenza A virus. Frontiers in Microbiology, 0, 14, .	3.5	0
629	Characteristics and anatomic location of PD-1 <sup>+</sup> TCF1 <sup>+</sup> stem-like CD8 T cells in chronic viral infection and cancer. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	7.1	3
630	Usp22 Deficiency Leads to Downregulation of PD-L1 and Pathological Activation of CD8+ T Cells and Causes Immunopathology in Response to Acute LCMV Infection. Vaccines, 2023, 11, 1563.	4.4	1
632	Bibliometric and visual analyses of trends in the field of T cell exhaustion research: Findings from 2000 to 2022. International Journal of Immunopathology and Pharmacology, 2023, 37, .	2.1	0
633	Commensal bacteria promote type I interferon signaling to maintain immune tolerance in mice. Journal of Experimental Medicine, 2024, 221, .	8.5	2
634	Emergence and fate of stem cell–like <i>Tcf7</i> <sup>+</sup> CD8 <sup>+</sup> T cells during a primary immune response to viral infection. Science Immunology, 2023, 8, .	11.9	2
636	Differential kinetics of splenic CD169+ macrophage death is one underlying cause of virus infection fate regulation. Cell Death and Disease, 2023, 14, .	6.3	0

#	Article	IF	CITATIONS
637	A longitudinal molecular and cellular lung atlas of lethal SARS-CoV-2 infection in K18-hACE2 transgenic mice. EBioMedicine, 2024, 99, 104932.	6.1	0
638	The crucial regulatory role of type I interferon in inflammatory diseases. Cell and Bioscience, 2023, 13,	4.8	2
639	Immunosurveillance encounters cancer metabolism. EMBO Reports, 2024, 25, 471-488.	4.5	0
640	Type 1 interferons and Foxo1 down-regulation play a key role in age-related T-cell exhaustion in mice. Nature Communications, 2024, 15, .	12.8	0
641	IFNα Subtypes in HIV Infection and Immunity. Viruses, 2024, 16, 364.	3.3	0
643	Autoimmunity-associated allele of tyrosine phosphatase gene PTPN22 enhances anti-viral immunity. PLoS Pathogens, 2024, 20, e1012095.	4.7	0